Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04158687 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
A Phase 2 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
NCT04158687 is a Phase 2 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 326 participants.
The verdict
NCT04158687, a Phase 2 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily (QD) for 12 weeks to adult participants with schizophrenia on stable dopaminergic antipsychotic medication.
Interventions
- DRUG Placebo
- DRUG CTP-692
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2019-11-26 |
| Est. Completion | 2020-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04158687
The ClinicalTrials.gov registry entry for NCT04158687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04158687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04158687 about?
NCT04158687 is a clinical study titled "A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia". The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily (QD) for 12 weeks to adult participants with schizophrenia on stable dopaminergic antipsychotic medication.
What is the current status of trial NCT04158687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2019-11-26. Estimated completion is 2020-12-22.
What interventions are being tested in trial NCT04158687?
The interventions under investigation include: Placebo (DRUG), CTP-692 (DRUG).
Who is sponsoring clinical trial NCT04158687?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.